Evidence map›Paper›PMID 26146810›Full record

ArticleBone marrow transplantation2015

Allogeneic hematopoietic stem cell transplantation for poor-risk CLL: dissecting immune-modulating strategies for disease eradication and treatment of relapse.

M Hahn, S Böttcher, S Dietrich, U Hegenbart, M Rieger, P Stadtherr, A Bondong, R Schulz, M Ritgen, T Schmitt and 10 more

Abstract read
PubMed Publisher
In one paragraph

Article in Bone marrow transplantation, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
3.1field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 36 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Observational
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 5 institutions in 1 country.

M HahnDepartment Medicine V, University of Heidelberg, Heidelberg, Germany.
S BöttcherDepartment Medicine II, University of Schleswig-Holstein, Campus Kiel, Kiel, Germany.
S DietrichDepartment Medicine V, University of Heidelberg, Heidelberg, Germany.
U HegenbartDepartment Medicine V, University of Heidelberg, Heidelberg, Germany.
M RiegerDepartment Medicine V, University of Heidelberg, Heidelberg, Germany.
P StadtherrDepartment Medicine V, University of Heidelberg, Heidelberg, Germany.
A BondongDepartment Medicine V, University of Heidelberg, Heidelberg, Germany.
R SchulzDepartment Medicine V, University of Heidelberg, Heidelberg, Germany.
M RitgenDepartment Medicine II, University of Schleswig-Holstein, Campus Kiel, Kiel, Germany.
T SchmittDepartment Medicine V, University of Heidelberg, Heidelberg, Germany.
T H TranTransplantation Immunology, University of Heidelberg, Heidelberg, Germany.
M GörnerStädtisches Klinikum and Onkologische Praxis, Bielefeld, Germany.
I HerthDepartment Medicine V, University of Heidelberg, Heidelberg, Germany.
T LuftDepartment Medicine V, University of Heidelberg, Heidelberg, Germany.
S SchönlandDepartment Medicine V, University of Heidelberg, Heidelberg, Germany.
M Witzens-HarigDepartment Medicine V, University of Heidelberg, Heidelberg, Germany.
T ZenzDepartment Medicine V, University of Heidelberg, Heidelberg, Germany.
M KnebaDepartment Medicine II, University of Schleswig-Holstein, Campus Kiel, Kiel, Germany.
A D HoDepartment Medicine V, University of Heidelberg, Heidelberg, Germany.
P DregerDepartment Medicine V, University of Heidelberg, Heidelberg, Germany.
Heidelberg University · DEKiel University · DEGerman Cancer Research Center · DEKlinikum Bielefeld · DEPraxis für Hämatologie und Onkologie · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To elucidate factors contributing to the effectiveness of allogeneic hematopoietic stem cell transplantation (alloHCT) in high-risk CLL, immune interventions, GvHD and clinical outcome of 77 consecutive patients allografted for CLL were analyzed. Immune modulation (immunosuppression tapering, rituximab-augmented donor lymphocyte infusions) was guided by minimal residual disease (MRD) monitoring and commenced at a median of 91 (22-273) days after alloHCT, resulting in a probability of being event free and MRD-negative 1 year after transplant of 57% (84% in those encountering chronic GvHD). Patients who were event free and MRD-negative at the 12-month landmark had a 4-year PFS of 77% and largely remained durably MRD-negative if MRD clearance had occurred subsequent to immune modulation. Three-year overall survival, PFS, relapse incidence and non-relapse mortality of all 77 patients were 69, 57, 26 and 24%, respectively. Survival was not affected by EBMT risk category but by active disease at alloHCT, which could not be overcome by intensification of conditioning. Twenty-three patients who experienced relapse post alloHCT had a survival of 56% at 2 years after CLL recurrence. In conclusion, MRD-guided immune modulation after alloHCT for high-risk CLL can provide durable MRD clearance in more than half of the patients.

Indexed as

AdultAgedDisease EradicationFemaleHematopoietic Stem Cell TransplantationHumansLeukemia, Lymphocytic, Chronic, B-CellMaleMiddle AgedNeoplasm Recurrence, LocalRecurrenceRetrospective StudiesTransplantation ConditioningTransplantation, HomologousTreatment Outcome

Identifiers

PMID26146810
OpenAlexW1551467549

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.